Latest From Inotrem SA
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in August and September.
BioNTech has plenty of cash and is gearing up for an IPO, but money from a Hong Kong investor is in limbo. Plus, Satsuma and SpringWorks bring US IPO total to 34 this year, Fate's FOPO raises $150.5m and Pharvaris brings in $66m.
Companies filling positions include Sanofi, with a new head of business transformation, and MSD Research Laboratories, with a leader for its new London early discovery facility. There is new leadership for Pandion Therapeutics, and further C-suite appointments at Orchard Therapeutics, Redx Pharma, Glythera and Inotrem.
In our 11th annual analysis of Series A financings, we look at five sub-species of A round investors, their habits, habitats, and behaviors during 2014.
- Therapeutic Areas
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- Inotrem SA
- Senior Management
Jean-Jaques Garaud, PhD, CEO
Marc Derive, PhD, CSO
- Contact Info
Phone: 9 66 81 79 00
114 rue la Boétie
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.